| Literature DB >> 35456575 |
Jui Fang1, Ming-Wei Lai2, Hao-Tsai Cheng3,4, Anca Cristea5, Zhuhuang Zhou6, Po-Hsiang Tsui2,7.
Abstract
Hepatic steatosis causes nonalcoholic fatty liver disease. Whole-body vibration (WBV) has been recommended to allow patients who have difficulty engaging in exercise to improve the grade of hepatic steatosis. This study proposed using ultrasound parametric imaging of the homodyned K (HK) distribution to evaluate the effectiveness of WBV treatments in alleviating hepatic steatosis. Sixty mice were assigned to control (n = 6), sedentary (n = 18), WBV (n = 18), and exercise (swimming) (n = 18) groups. Mice were fed a high-fat diet to induce hepatic steatosis and underwent the intervention for 4, 8, and 16 weeks. Ultrasound scanning was performed in vivo on each mouse after the interventions for ultrasound HK imaging using the parameter μ (the scatterer clustering parameter). Histopathological examinations and the intraperitoneal glucose tolerance test were carried out for comparisons with ultrasound findings. At the 16th week, WBV and exercise groups demonstrated lower body weights, glucose concentrations, histopathological scores (steatosis and steatohepatitis), and μ parameters than the control group (p < 0.05). The steatosis grade was significantly lower in the WBV group (mild) than in the exercise group (moderate) (p < 0.05), corresponding to a reduction in the μ parameter. A further analysis revealed that the correlation between the steatosis grade and the μ parameter was 0.84 (p < 0.05). From this animal study we conclude that WBV may be more effective than exercise in reducing the progression of hepatic steatosis, and ultrasound HK parametric imaging is an appropriate method for evaluating WBV's effect on hepatic steatosis.Entities:
Keywords: envelope statistics; hepatic steatosis; ultrasound; whole-body vibration
Year: 2022 PMID: 35456575 PMCID: PMC9028833 DOI: 10.3390/pharmaceutics14040741
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1Illustration of the experimental design, including (A) animal preparation; (B) interventions; (C) ultrasound data analysis; (D) ultrasound backscattering analysis; (E) MetS evaluations and histopathological examinations.
Figure 2Ultrasound HK μ parametric images of mouse liver in various groups and intervention periods. CON: control; SED: sedentary; WBV: whole-body vibration. The delineated contours described by white dotted lines represent the ROIs for the data analysis.
Figure 3Hematoxylin-and-eosin-stained liver sections obtained from various groups and during different intervention periods. CON: control; SED: sedentary; WBV: whole-body vibration. Black arrows represent vessels; some of them contain red blood cells. Yellow arrows indicate fatty vesicles.
Changes in steatosis, steatohepatitis, and fibrosis in the sedentary group (the normality test failed, and thus ANOVA on ranks was applied).
| Parameter | Control Group | SED for 4 Weeks | SED for 8 Weeks | SED for 16 Weeks | |
|---|---|---|---|---|---|
| 0.64, 0.75, 0.67 | 0.74, 0.56, 0.76 | 0.69, 1.11, 0.74 | 2.08, 4.15, 3.94 | 7.26 × 10−6 | |
| Weight (g) | 17.43, 18.55, 18.22 | 27.06, 26.63, 26.76 | 37.21, 38.69, 39.52 | 42.76, 43.17, 42.3 | 4.76 × 10−15 |
| Peak of glucose concentration (mg/dL) | 231, 249, 237 | 413, 402, 429 | 361, 509, 481 | 447, 493, 463 | 4.35 × 10−9 |
| Steatosis | 0,0, 0, 1, 0, 0 | 1, 1, 0, 0, 0, 0 | 0, 0, 0, 2, 1, 0 | 2, 3, 3, 2, 2, 3 | 3.14 × 10−6 |
| Lobular inflammation | 1, 1, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 1, 0, 0, 1 | 0.26 |
| Hepatocyte ballooning | 1, 1, 0, 0, 0, 0 | 1, 1, 0, 0, 0, 0 | 0, 1, 0, 1, 1, 0 | 2, 2, 2, 2, 2, 2 | 4.75 × 10−6 |
| Steatohepatitis | 2, 2, 0, 1, 0, 0 | 2, 2, 0, 0, 0, 0 | 0, 1, 0, 3, 1, 0 | 4, 5, 6, 4, 4, 6 | 1.22 × 10−6 |
| Fibrosis | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 1 |
Steatohepatitis = the unweighted sum of the score of steatosis (score, 0–3), lobular inflammation (score, 0–3), and hepatocyte ballooning (score, 0–2), and thus ranges from 0 to 8.
Changes in steatosis, steatohepatitis, and fibrosis in the exercise group (the normality test failed, and thus ANOVA on ranks was applied).
| Parameter | Control Group | Exercise for 4 Weeks | Exercise for 8 Weeks | Exercise for 16 Weeks | |
|---|---|---|---|---|---|
| 0.64, 0.75, 0.67 | 0.82, 0.52, 0.85 | 2.32, 0.72, 0.59 | 2.10, 3.18, 2.45 | 1.78 × 10−5 | |
| Weight (g) | 17.43, 18.55, 18.22 | 24.23, 23.46, 25.67 | 37.96, 36.11, 35.14 | 38.51, 39.87, 39.82 | 3.48 × 10−20 |
| Peak of glucose concentration (mg/dL) | 231, 249, 237 | 409, 396, 422 | 462, 335, 348, | 382, 447, 399, | 1.66 × 10−6 |
| Steatosis | 0,0, 0, 1, 0, 0 | 1, 0, 1, 0, 0, 0 | 2, 1, 0, 1, 0, 1 | 1, 2, 2, 3, 2, 1 | 0.0007 |
| Lobular inflammation | 1, 1, 0, 0, 0, 0 | 0, 1, 1, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 1, 0, 0, 0, 0, 0 | 0.42 |
| Hepatocyte ballooning | 1, 1, 0, 0, 0, 0 | 1, 1, 0, 0, 0, 0 | 2, 0, 2, 0, 0, 0 | 2, 2, 2, 2, 2, 1 | 0.0023 |
| Steatohepatitis | 2, 2, 0, 1, 0, 0 | 2, 2, 2, 0, 0, 0 | 4, 1, 2, 1, 0, 1 | 4, 4, 4, 5, 4, 2 | 0.0005 |
| Fibrosis | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 1 |
Steatohepatitis = the unweighted sum of the score of steatosis (score, 0–3), lobular inflammation (score, 0–3), and hepatocyte ballooning (score, 0–2), and thus ranges from 0 to 8.
Changes in steatosis, steatohepatitis, and fibrosis in the whole-body vibration group (the normality test failed, and thus ANOVA on ranks was applied).
| Parameter | Control Group | WBV for 4 Weeks | WBV for 8 Weeks | WBV for 16 Weeks | |
|---|---|---|---|---|---|
| 0.64, 0.75, 0.67 | 0.74, 0.61, 0.72 | 1.13, 2.37, 1.18 | 0.75, 0.72, 1.05 | 0.25 | |
| Weight (g) | 17.43, 18.55, 18.22 | 26.01, 25.49, 24.45 | 31.29, 38.12, 36.21 | 40.38, 40.76, 41.19 | 6.69 × 10−13 |
| Peak of glucose concentration (mg/dL) | 231, 249, 237 | 401, 392, 397 | 486, 495, 471, | 420, 431, 444, | 4.38 × 10−7 |
| Steatosis | 0,0, 0, 1, 0, 0 | 0, 1, 0, 0, 0, 0 | 1, 2, 0, 0, 0,0 | 1, 1, 1, 2, 1, 0 | 0.0808 |
| Lobular inflammation | 1, 1, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 1, 1, 1, 1, 0, 2 | 0.0011 |
| Hepatocyte ballooning | 1, 1, 0, 0, 0, 0 | 0, 0, 1, 0, 0, 0 | 2, 1, 1, 1, 0, 0 | 1, 2, 2, 2, 2, 1 | 0.0007 |
| Steatohepatitis | 2, 2, 0, 1, 0, 0 | 0, 1, 0, 1, 0, 0 | 3, 3, 1, 1, 0, 0 | 3, 4, 4, 5, 3, 3 | 4.07 × 10−5 |
| Fibrosis | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 0, 0, 0, 0, 0, 0 | 1 |
Steatohepatitis = the unweighted sum of the score of steatosis (score, 0–3), lobular inflammation (score, 0–3), and hepatocyte ballooning (score, 0–2), and thus ranges from 0 to 8.
Figure 4Changes in MetS, histopathological, and ultrasound examination results across the intervention periods. (a) Body weight, (b) glucose concentration, (c) steatosis, (d) lobular inflammation, (e) hepatocyte ballooning, (f) steatohepatitis, and (g) HK μ parameter (* p < 0.05).
Figure 5HK μ parameters as functions of MetS and histopathological scores (across all groups). The Spearman correlation coefficient was calculated. (a) Body weight, (b) glucose concentration, (c) steatosis, (d) lobular inflammation, (e) hepatocyte ballooning, and (f) steatohepatitis. No correlation was observed in (d).